Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE

By sjmartinez • January 22, 2025

Grinspoon SK, Zanni MV, Triant VA, Kantor A, Umbleja T, Diggs MR, Chu SM, Fitch KV, Currier JS, Bloomfield GS, Casado JL, de la Peña M, Fantry LE, Gardner E, Aberg JA, Malvestutto CD, Fichtenbaum CJ, Lu MT, Ribaudo HJ, Douglas PS. Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE. Lancet HIV. 2025 Jan 17:S2352-3018(24)00276-5. doi: 10.1016/S2352-3018(24)00276-5. Epub ahead of print. PMID: 39832519.

Tags: Infectious Diseases, Publications

Related Posts

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

Shumaker AH, Bhimraj A, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Shafer RW, Tien PC, Baden LR, Cawcutt K, Chiotos K, Dzierba[...]

Lem3, a phospholipid flippase subunit, influences Candida albicans pathogenicity through maintenance of plasma membrane asymmetry

Agrawal P, Kumar P, Ali B, Nabeela S, Ikeh MAC, Morschhäuser J, Andes DR, Nobile CJ, Prasad R, Uppuluri P, Panwar SL. Lem3, a phospholipid[...]